Takaisin

Effects of metabolic bariatric surgery compared to other treatments on weight loss, mortality and cardiovascular morbidity in patients with obesity

Näytönastekatsaukset
Jorma Komulainen
17.11.2026

Level of evidence: A

Metabolic bariatric surgery (MBS) for patients with obesity results in a mean weight loss of approximately 18% of the initial body weight (95 % confidence interval 15 to 21%), when compared to lifestyle interventions (LSI), medical treatment (MT) or their combination (LSI/MT) in long term follow-up.

The effects are similar on body mass index (BMI) (high level of evidence) and body weight (high level of evidence) in long-term follow-up.

Compared to treatment with GLP1 receptor antagonists (GLP1-RAs), MBS increases the percentage of patients achieving a sustainable weight reduction of 5% or 10% by around 27% and 51% in 2 years of follow-up (low level of evidence).

Compared to treatment as usual, MBS probably decreases total mortality by around 29%, cardiovascular mortality by around 53% and cardiovascular events by around 33% in 2-16 years of follow-up (moderate level of evidence).

In face-to-face comparisons, Roux-en-Y gastric bypass (RYGB) might be slightly more effective than sleeve gastrectomy (SE) in the reduction of BMI and weight loss (low level of evidence). However, in network meta-analysis, no clear superiority of one type of surgical procedure over the others was observed.

Comment: The meta-analysis «De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 did not report which medications were used, therefore some of the most recent studies on efficient medications might be lacking in the comparisons.

Table 1. Description of the included studies
Reference Study type Population Intervention and comparison Outcomes Risk of bias «Additional comments for included studies...»2
RCT=randomized controlled trial; with usual treatment SR=systematic review; MA=meta-analysis
«De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 MA including RCTs with a duration of at least 52 weeks Altogether 65 trials (6 271 patients) including patients with overweight or obesity Various metabolic and bariatric surgery (MBS) methods vs. lifestyle intervention (LSI), medical therapy (MT), both (LSI/MT) or another MBS method Principal endpoint: BMI at the end of study period. Secondary endpoints: body weight, fat mass, percentage of weight loss, fasting plasma glucose, HbA1C, lipid profile, blood pressure, serious adverse events, mortality, diabetes remission, hypertension and dyslipidemia remission, quality of life, obstructive sleep apnea syndrome Moderate
«Barrett TS, Hafermann JO, Richards S, et al. Obesi...»2 Cohort study 30458 patients (14101 with MBS, 16357 receiving GLP-1 RAs); mean age 50 years; 66.1% female MBS (sleeve or gastric by-pass) vs. medication with GLP-1 receptor antagonist Primary endpoints:
The mean total costs per month
at baseline and within the first and second year after index treatment, as well as the total costs over 2 years.
Weight loss of 5% and 10% until the end of follow-up period.
Secondary endpoints:
Health care utilization and changes in the rates of obesity-related comorbidities at follow-up.
High
«Sjöström L. Review of the key results from the Swe...»3 Case-control study Altogether 2010 patients with obesity who underwent MBS and 2037 patients with obesity MBS (gastric bypass (13%), banding (19%), vertical banded gastroplasty (68%) versus matched controls receiving usual care Primary endpoint:
Mortality
Secondary endpoints:
Weight loss, cardiovascular disease, diabetes, biliary disease, quality of life and cost efficiency
Moderate
Table 2. Additional comments for included studies
Reference Comments
«De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 All trials were open-label. In several trials, the reporting of allocation, blinding of assessors or attrition was inadequate. In addition, reporting bias and defects in the randomization process could not be excluded in some of the studies.
The mean follow-up time for all the studies included was 3.6 years (185.4 weeks,range: 52 to 520 weeks).
«Barrett TS, Hafermann JO, Richards S, et al. Obesi...»2 The cohort study was based on electronic health records and conducted between 2018 and 2023. The data for the percentage of patients with sustained weight loss of 5 and 10% was available only for a small minority of the study population (1548 out of 30458 patients).
Patients treated with GLP1-RAs were older compared to patients treated with MBS, (mean age 49 yrs vs. 44 yrs).
«Sjöström L. Review of the key results from the Swe...»3 Only the results for mortality and cardivascluar events are reported here. The control group consisted of patients with obesity matched by gender, age, weight, height, waist and hip circumferences, systolic blood pressure, serum cholesterol and triglyceride levels, smoking status, diabetes, menopausal status, four psychosocial variables with documented associations with the risk of death and two personality traits related to treatment preferences.
The control group's treatment varied from sophisticated lifestyle interventions and behavioral modification programs to, in many practices, no treatment at all.

Results

Table 3. Effect of bariatric surgery vs. lifestyle intervention and/or medical treatment on BMI.
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Mean difference, kg/m2 (95% CI)
Level of evidence: high
I= intervention; C=comparison; CI=confidence interval
«De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 All trials:
20 (690/606)
Patients with BMI > 34.9 kg/m2:
7 (182, 163)
Trials enrolling only patients with BMI > 34.9 kg/m2:
8 (292, 221)
52 weeks or more All trials:
-6.01 (-6.93 to -5.09)
Patients with BMI > 34.9 kg/m2:
-8.34 (-10.43to -6.25)
Trials enrolling only patients with BMI > 34.9 kg/m2:
-7.29 (-10.21 to -4,36)
Table 4. Effect of bariatric surgery vs. lifestyle intervention and/or medical treatment on body weight.
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Mean difference, kg (95% CI)
Level of evidence: high
I= intervention; C=comparison; CI=confidence interval
«De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 16 (536/448) 52 weeks or more -18.99 (-22.73 to -15.25)
Table 5. Effect of bariatric surgery vs. lifestyle intervention and/or medical treatment on weight loss (percentage of initial body weight lost) .
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Relative effect, % (95% CI)
Level of evidence: high
I= intervention; C=comparison; CI=confidence interval
«De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 13 (425,323) 52 weeks or more -17.70 (-14.54 to -20.87)
Table 6. Effect of bariatric surgery vs. GLP1-Ras medication on percentage of patients starting with a BMI of 40 kg/m2 or more and receiving a sustained 5% or 10% weight loss.
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Relative effect, % (95% CI)
Level of evidence: low
The quality of evidence is downgraded due to very serious study limitations and upgraded due to large magnitude of the effect.
«Barrett TS, Hafermann JO, Richards S, et al. Obesi...»2 1 (1291, 257) 2 years or more 5% reduction:
1275 (98.8)
10% reduction:
1239 (96.0)
5% reduction:
184 (71.6)
10% reduction:
118 (45.9)
5% reduction:
27.2% (21.7 to 32.8)
10% reduction:
50.1% (43.9 to 56.3)
Table 7. Effect of bariatric surgery versus treatment as usual on cumulative mortality and cardiovascular events (CVE).
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Adjusted risk reduction, % (95% CI)
Level of evidence: moderate
The quality of evidence is downgraded due to serious study limitations and upgraded due to large magnitude of the effect.
«Sjöström L. Review of the key results from the Swe...»3 1 (2001, 2027) 2 to 16 years Mortality:
101 (5.02)
Total CVE:
199 (9.90)
Fatal CVE:
28 (1.39)
Mortality:
129 (6.33)
Total CVE:
234 (11.49)
Fatal CVE:
49 (2.40)
Mortality:
29% (46 to 8)
Total CVE:
33% (46 to 17)
Fatal CVE:
53% (71 to 24)
Table 8. Effect of Roux-en-Y gastric by-pass (RYGB) versus sleeve gastrectomy (SG) on BMI (kg/m2), body weight (kg, %).
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Mean difference (95% CI)
Level of evidence: low
The quality of evidence is downgraded due to inconsistency (I2 85%, 83% and 91%) and imprecision.
«De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 BMI:
16 (651/746)
Body weight:
Absolute:10 (399/396)
Percentage:
11 (398/493)
52 weeks or more BMI:
-1.30 (-2,45, -0,14)
Body weight:
Absolute
-3,01 kg (-8,41, 2,39)
Percentage: -4,80% (1,35, 8,26)

References

  1. De Luca M, Zese M, Silverii GA, et al. Bariatric Surgery for Patients with Overweight/Obesity. A Comprehensive Grading Methodology and Network Metanalysis of Randomized Controlled Trials on Weight Loss Outcomes and Adverse Events. Obes Surg 2023;33(12):4147-4158 «PMID: 37917391»PubMed
  2. Barrett TS, Hafermann JO, Richards S, et al. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA Surg 2025;160(11):1232-1239 «PMID: 40960852»PubMed
  3. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273(3):219-34 «PMID: 23163728»PubMed